Arcadia Biosciences, Inc.
RKDA
$0.47
$0.000.23%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -12.24% | -9.53% | -3.73% | 12.29% | 23.81% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -12.24% | -9.53% | -3.73% | 12.29% | 23.81% |
| Cost of Revenue | -4.67% | 1.92% | 8.60% | 40.16% | 64.91% |
| Gross Profit | -23.71% | -25.55% | -19.87% | -13.22% | -10.11% |
| SG&A Expenses | -37.84% | -30.89% | -27.41% | -6.79% | 5.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.85% | -22.76% | -19.17% | 2.68% | 16.90% |
| Operating Income | 42.45% | 32.53% | 29.62% | 4.37% | -11.80% |
| Income Before Tax | -57.33% | -1,122.44% | 45.89% | -595.03% | -3,806.08% |
| Income Tax Expenses | 0.00% | 0.00% | 0.00% | 14.29% | 14.29% |
| Earnings from Continuing Operations | -57.26% | -1,110.78% | 45.81% | -589.47% | -3,664.89% |
| Earnings from Discontinued Operations | -- | -- | -- | 99.47% | 93.07% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.72% | -362.45% | 66.77% | 13.04% | -11.10% |
| EBIT | 42.45% | 32.53% | 29.62% | 4.37% | -11.80% |
| EBITDA | 42.14% | 32.20% | 28.98% | 2.83% | -15.42% |
| EPS Basic | 17.60% | -286.53% | 66.94% | 13.28% | -10.71% |
| Normalized Basic EPS | 59.49% | -22.30% | 37.62% | -71.59% | -147.65% |
| EPS Diluted | 17.42% | -196.99% | 69.38% | 21.40% | -1.66% |
| Normalized Diluted EPS | 59.46% | -51.66% | 26.45% | -137.39% | -261.71% |
| Average Basic Shares Outstanding | 43.07% | 13.40% | 0.35% | 0.28% | 0.30% |
| Average Diluted Shares Outstanding | 43.16% | -14.84% | -24.65% | -24.71% | -24.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |